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Analysis of data on cancer incidence rates in different countries at different time periods revealed 
positive association between overall cancer risk and economic progress. Typical explanations of 
this phenomenon involve improved cancer diagnostics and elevated exposure to carcinogens in 
industrial countries. Here we provide evidence from human and experimental animal studies 
suggesting that some other factors associated with high economic development and Western life 
style may primarily increase the proportion of susceptible to cancer individuals in a population 
and thus contribute to elevated cancer risks in industrial countries. These factors include (but not 
limited to):  (i) better medical and living conditions that “relax” environmental selection and 
increase share of individuals prone to chronic inflammation; (ii) several medicines and foods that 
are not carcinogenic themselves but affect the metabolism of established carcinogens; (iii) 
nutrition enriched with growth factors; (iv) delayed childbirth. The latter two factors may favor 
an increase in both cancer incidence rate and longevity in a population. This implies the presence 
of a trade-off between cancer and aging: factors that postpone aging may simultaneously 
enhance organism’s susceptibility to several cancers.  
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1.1 Why focus on Overall Cancer Risk?  
Cancer is the generic term for more than 100 diseases, each characterized by a specific etiology, 
pathogenesis, and tissue localization. The development of cancer has multiple causes, including 
genetic predisposition, infectious agents, and exposure to chemical or physical carcinogens. Can 
we discuss risk factors that are common for a set of different diseases? As far as cancer is 
concerned, this is justified because most cancers share common key features. They include 
uncontrolled abnormal growth of cells, their potential immortality, de-differentiation, and 
capacity for invasion and metastasis (Abelev 1997, Bast et al. 2000, Hanahan and Weinberg 
2000). These common features suggest that there exist common risk factors for different cancers. 
For instance, chronic inflammation is one such factor because it promotes almost all cancer 
features described above (Coussens and Werb 2002). If some factors linked to economic 
progress favor an increase in the proportion of people with chronic inflammation, these factors 
may simultaneously increase cancer risk in a given population. On the other hand, if there is 
successful treatment for an inflammatory disease, then the risks of relevant cancers may decline.  
 
1.2 Why is the Overall Cancer Risk Higher in More Developed Countries?  
Our analysis of epidemiological data on cancer incidence rates in different countries and at 
different time periods revealed a positive association between the level of economic development 
and the overall cancer risk (see paper I. Puzzling Facts of Cancer Epidemiology). Typical 
explanations focus on improved cancer diagnostics and elevated exposure to carcinogens.  
       Here, we provide compelling evidence from human and animal studies suggesting that 
several other factors associated with high economic development and a Western life-style make 
substantial contributions to rising cancer risks. These factors influence the proportion of 
individuals vulnerable to cancer rather than the carcinogenic exposure in a population.  3
They include improvements in medical care and living conditions, which “relax” environmental 
selection and increase the share of people prone to chronic inflammation (the latter is an 
important cancer promoting factor). Several factors specific to a Western life-style (e.g., new 
foods and medicines) may enhance individual susceptibility to cancer. Not essentially 
carcinogenic themselves, these affect the metabolism of established carcinogens and thus have 
the potential to favor cancer risks. In addition, there are factors that influence both an organism’s 
aging and vulnerability to cancer. For example, food enriched with growth factors or delayed 
childbirth may affect some characteristics of aging and development (such as the duration of the 
growth period, the ages of menarche and menopause, parental age, height, and weight), so that it 
would favor a postponement of aging manifestation and an increase in longevity. These same 
factors may also enhance individual vulnerability to cancer (to be discussed). This implies the 
presence of a trade-off between cancer and aging: Factors that postpone aging may 
simultaneously elevate cancer incidence rate in a population.  
 
2 Improved Cancer Diagnostics  
2.1 Improved Diagnostics Does not Fully Explain Rising Cancer Risks  
Improved cancer diagnostics allows for the earlier detection of tumors and/or the better 
identification of the disease. Both factors can contribute to an increase in the cancer incidence 
rate and are often considered to be major causes of such a rise. However, this assumption, while 
valid for some cancers (e.g., of the prostate), does not seem to have a solid empirical basis for 
many other cancer sites. Here, we examine the effects of improved cancer diagnostics on cancer 
incidence rates, taking into account some accompanying factors, such as the spontaneous 
regression of tumors, survival of cancer patients and sex differences, to show that improved 
diagnostics does not fully explain the rise in cancer risks.  
 
2.2 Improved Identification of Tumors 
More efficient methods of cancer diagnostics allow for the identification of tumors that would 
not be detected by current methods. The former increases the total number of cancers detected in 
individuals of selected age groups. It is reasonable to assume that for each age category the 
number of additional tumors identified with improved diagnostics is proportional to the number 
of tumors detected by current methods. The new cancer incidence rate would then increase faster 
with age than the old one. This prediction corresponds to available data, suggesting that the 4
improved identification of tumors contributes to a rise in cancer incidence rates in developed 
countries (Figure1).  
Figure 1 about here 
 
Some clinical studies provide supporting evidence for this conclusion. In a study of 
histologically detected adenocarcinomas of the prostate involving 179,298 men in the 
Netherlands, Giard and co-authors (1998) explained most of the increase in the incidence rate of 
this cancer between 1990 and 1996 by more intensive diagnostics with prostate-specific antigen 
(PSA) and transrectal ultrasonography. Some other studies, however, suggested that the impact 
of improved diagnostics (particularly routine PSA testing) on the rate of incidental prostate 
cancer is less substantial (Zigeuner et al. 2003). Improved diagnostics may explain at least part 
of the steep increase (by almost 200 percent) in the incidence rate of prostate cancer that 
occurred over the last 50 years (Ries et al. 2001).  
               It is unlikely, however, that the improved identification of tumors is responsible for the 
enormous increases in the risks of many other cancers such as melanoma of the skin, lung 
cancer, myeloma and non-Hodgkin lymphoma. Together, these cancers contributed to a large 
extent to the growth in the overall cancer risk during the second half of the last century. Their 
rates in the USA rose by about 200- 500 percent during this period (Ries et al. 2001). There is no 
convincing evidence that only improved diagnostics accounts for such an enormous elevation of 
the rates. Furthermore, some studies show that there has been no radical improvement in the 
detection of lung cancer, melanoma of skin, and myeloma (sites that have the highest increase in 
the rate) (De Rooij et al. 1996, Hirsch et al. 2002).  
              Female breast cancer rates have risen less rapidly but still substantially (about 70 
percent) during the last 50 years in the USA (Ries et al. 2001). New methods of mass screening 
using mammography added only about 1 percent of new cancer cases to those detected by 
ordinary physical examination (Morimoto et al. 1994). The rate of female breast cancer 
drastically increased 1960-62 and 1988-92 in Moscow (Russia) (see Chapter 2.1). This rise took 
place without a population-wide application of new cancer detection methods, and hence 
requires a different explanation. 
           For some cancer sites, the incidence rates are higher in less developed countries. 
Examples include cervix, esophagus, stomach, and liver cancers. Their elevated rates naturally 
can not be attributed to improved cancer diagnostics in less developed countries. Cervical and 
stomach cancers have been showing a decline in the risks by about 80 percent in the USA during 5
the last 50 years (Ries et al. 2001). Again, the fall in incidence rates could not have occurred as a 
result of improved diagnostics of these cancers. If so, then why should one a priori accept the 
pivotal role of improved diagnostics in the increased risks of other cancers? 
          We conclude that improved identification of tumors partly contributes to the contemporary 
increase in the overall cancer risk in developed countries. However, it is unlikely to be the only 
factor responsible for such an increase.  
 
2. 3 Effects of Early Detection  
Early detection alone. Consider a hypothetical situation: New methods of cancer diagnostics 
detect about the same number of cancer cases as the older technology, but at earlier ages. What 
would the effect be on cancer incidence rate curves? Let us ignore the possibility of detecting 
tumors that regressed spontaneously thereafter, and would therefore not have been observed with 
the older technology. Let us also ignore the effect of dying from competing causes.  In this case, 
one may expect that the new age-specific cancer incidence rate can be produced from the old one 
by a parallel shift of the former incidence rate to the left. Figure 1 above shows that the change in 
cancer risks over time does not follow this pattern. We can see from this figure that the new 
incidence rate increases faster with age than the old one.  
Decline in the tumor growth rate with age. The rate of tumor growth commonly declines 
at old ages in cancer patients (Peer et al. 1993, Semiglazov et al. 1989, Kozma 1998, Maehara et 
al. 1996). Possible reasons are discussed by Ukraintseva and Yashin (2003). With this decline, 
improved diagnostics will detect tumors with longer durations of growth at older ages than at 
younger ages. This may contribute to the higher incidence rate at older ages by shifting the entire 
incidence rate curve to the left. 
Spontaneous tumor regression. The earlier detection may include tumors that will later 
regress spontaneously. Here, the total of newly detected tumors may be higher than observed 
with former methods of diagnostics. To produce a faster increase in the incidence rate, the new 
methods of cancer diagnostics must detect more cases of spontaneously regressed tumors in the 
elderly than in youth and adulthood. This scenario, however, does not seem realistic because the 
majority of spontaneously regressed tumors arise in infancy. Infant neuroblastoma is an example 
of a cancer with a high propensity to spontaneous regression (Ries et al. 1999).    
Survival of cancer patients. The most important effect of early tumor detection is, 
obviously, the better survival of cancer patients. This is because earlier detected tumors have a 
higher chance of being curable, and because early detection may reveal more tumors with a 6
propensity to spontaneous regression. Both factors increase the share of patients surviving 
cancer. If earlier detection is also responsible for a rise in the cancer incidence rate, then we can 
expect a higher survival rate of cancer patients in countries with higher incidence rates (Figure 
2).  
 
 Figure 2 is about here 
 
We see from this figure that there is no clear relationship between cancer incidence and 
survival rates in European countries. For instance, the lowest incidence rates are in the UK and in 
Sweden, which are countries manifesting the worst and the best survival from cancer, 
respectively. The lack of a positive correlation between incidence and survival suggests that 
more factors in addition to improved diagnostics are involved in creating higher overall cancer 
risks in more developed countries.  
 
2. 4 Sex Differences in Time Trends for the Same Cancer Site 
Lungs are one the most prevalent cancer sites in both males and females. Lung cancer 
substantially contributes to the overall cancer risk. A comparison between male and female 
trends in the incidence rate for this cancer suggests that improved cancer diagnostics accounts for 
only small portions of the rise in lung cancer risk. Figure 3 (1, 2) shows age-patterns of lung 
cancer incidence rates in different years, and the ratio of the rates 1960-1962 to 1988-1992 in the 
USA, by sex. 
Figure 3 (1, 2) about here 
 
   As can be seen from this figure, the relative increase in lung cancer risks between 1960-
62 and 1988-92 was much higher for females than for males, particularly at ages 50-80. This 
difference cannot be explained by improved lung cancer diagnostics, since the latter would have 
produced similar relative changes for both sexes.  
           In summary, the available data do not provide the grounds for explaining the increase in 
cancer risk solely by the improved quality of cancer diagnostics in more developed countries. 
Although better diagnostics may contribute to an increase in incidence rates for certain cancers 
(e.g., of the prostate), it can not explain multifold increases in the risk of cancer in other sites that 
are largely responsible for the increase in the overall rate in developed countries. Other factors, 
such as elevated exposure to environmental carcinogens, changes in the frailty distribution or 7
increasing individual susceptibility to cancer in modern human populations, may be more 
important. We discuss the role of these factors in the sections below.  
 
3 Elevated Exposures to Carcinogens  
3.1 Is the Increase in Cancer Risks due to Increased Carcinogenic Load?  
Another popular explanation of the higher overall cancer risk in more developed regions is the 
higher exposure of individuals to environmental carcinogens (e.g., linked to industrial pollution). 
How strong is the basis for such an explanation? In this section we show that the evidence of 
excess in the carcinogenic burden assumed to exist in more developed countries is not 
sufficiently substantial to explain the enormous differences in cancer risks between these and 
less developed countries. The change in the spectrum of prevalent carcinogens (sometimes 
resulting in decreased total carcinogenic exposure) may be a more important factor.   
 
3.2 Infections and Cancer 
Numerous studies stressed the important role of infection in the etiology of human cancers. The 
Helicobacter pylori, and Hepatitis and Papilloma viruses are examples of relevant infectious 
agents (IARC Monographs 1994a, b, 1995a;  EstEve et al. 1993, Parsonnet 1999, Brenner 2000). 
Helicobacter pylori are bacteria living in the pylorus. In some circumstances (e.g., lowered 
acidity), they move up into the stomach. The products of their metabolism contribute to an 
increase in the risk of stomach cancer (IARC Monographs 1994b). Infection with the Hepatitis B 
virus elevates the risk of liver cancer (IARC Monographs 1994a). The Papilloma virus was 
shown to elevate the risk of cervical cancer (IARC Monographs 1995b). The wide use of 
antibiotics, antiviral treatment, and vaccinations as well as higher levels of hygiene has lowered 
the exposure of human organisms to many kinds of infections in more developed countries. This 
partly explains the lower risks of infection-related cancers (e.g., of the stomach, cervix, and 
liver) in these countries compared to less developed ones. That is, exposure to some infection-
related carcinogens has been decreasing in parallel with economic progress. 
 
3.3 Many of Today's Carcinogens Existed and Were Even More Prevalent in the Past 
The IARC monographs on the Evaluation of Carcinogenic Risks to Humans, published between 
1972 and 2001, describe the results of studies on 869 agents and mixtures found in the modern 
environment. Only 10 percent (n=87) were established as clearly carcinogenic to humans (IARC 8
Monographs 1972-2001). Furthermore, most of these carcinogens not only existed in the past, 
but were equally, and sometimes more, prevalent.  
         For example, 25 manufacturers that use or produce various carcinogenic substances were 
listed in the reports on industrial exposure of humans to carcinogens. About half of the 
carcinogens existed in the beginning of the last century. Unhealthy working conditions and 
limited knowledge about cancer risk factors make it very likely that the people working at the 
manufacturing plants were exposed to carcinogens in the past to a higher extent than their 
counterparts of today. Industries associated with coal, soot, tar, and sawdust; shoe manufacturing 
and repairing; furniture and cabinet making; the rubber industry; and iron and steel production 
are examples (IARC Monographs 1987, 1995b).                   
         Practically every individual was permanently exposed in the past to some established 
carcinogens (e.g., coal, tar and soot) during normal home life. These common daily exposures 
have virtually ceased today.  
 
3.4 Increased Cancer Rates at a Time of Decreased Exposure to Tobacco Smoking 
Tobacco smoking is an established risk factor for many cancers. It is widely accepted that 
smoking today is responsible for the high incidence rate of lung cancer in males as well as for the 
increase in the incidence rate over time in females (Tominaga 1999). Let us consider the 
connection between smoking and trends in lung cancer risks in greater detail. 
Females are more vulnerable to smoking. As shown in Figure 3 above, lung cancer rates 
increased between 1960-62 and 1988-92 much more rapidly for females than for males, 
particularly at ages 50-80. The sex difference can be explained by higher susceptibility of the 
female organism to harmful tobacco products rather than by higher exposure of women to 
smoking compared to men.  
          Individual vulnerability to tobacco smoking depends on the presence of certain 
metabolizing enzymes (e.g., cytochromes P450), which convert nicotine and some other tobacco 
products into active carcinogens (Napalkov et al. 1987, Buters et al. 1999, Gonzalez 2000). For 
instance, the higher expression of the CYP1A1, a nicotine metabolizing enzyme, is shown to be 
associated with a higher risk of lung cancer among smokers. However, the expression of this 
enzyme is commonly higher in smoking women than in smoking men (Gonzalez 2000). That is, 
the female enzymatic system is likely to be more susceptible to nicotine than that of males. A 
large case-control study by the American Health Foundation confirmed the higher susceptibility 
to tobacco carcinogens in U.S. women (Zang and Wynder 1996). At the same level of tobacco 9
exposure, the odd ratios were 1.2-fold to 1.7-fold higher in women than in men for all three of 
the major histological types of lung cancer. This suggests that in a hypothetical case of the same 
increase in the proportion of smoking individuals among females and males, female cancer 
incidence rates would increase more rapidly over time. Has the proportion of smoking 
individuals increased over time, however?  
The share of smoking individuals has been declining since the 1960s. In 1955, nearly 
60 percent of white men in the USA were smokers. This proportion decreased through the 1960s 
to 50 percent. By 1974, male smoking dropped to less than 42 percent and this trend continued 
over the following decades. The data indicate that in 1994, only 27 percent of white men were 
smokers (Health US 2001). The proportion of smoking men in the USA thus decreased more 
than two-fold during the second half of the last century.  
         The proportion of smoking white females in the USA did not show such a steep decline 
over the same period. It increased from about 28 percent of white females in the 1950s to 34 
percent in 1965, followed by a decrease to 32 and 24 percent in 1974 and 1994, respectively.  
           Thus, the share of smoking individuals declined in the USA both in males and females. 
Today, the share is similar for the two sexes. The recent deceleration and even decline in male 
lung cancer incidence and mortality rates (Health US 2001, Cole et al. 1996, Ries et al. 2001) 
may be a reflection of the success of tobacco control efforts among men over the past decades. 
Contrarily, the continuing increase in female lung cancer risks cannot be explained by stronger 
female smoking habits because the proportion of smoking women has declined in the USA since 
1965. By 1994 the number of women smokers has been continuously declining for almost 30 
years. One may suggest that the increase in female lung cancer today is a reflection of the past 
increase in the proportion of female smokers of almost 40 years ago. Similarly, one may assume 
that the decline in male lung cancer risks, first observed in the 1990s, directly reflects the 
decrease in the proportion of male smokers, which first begun more than 30 years before the 
decline in cancer rates. Some studies of changes in the carcinogenic risks of tobacco smoking 
after smoking cessation support this possibility (Ebbert et al. 2003). However, other data suggest 
that the risk of lung cancer begins to decline shortly after stopping smoking, and that the odds 
ratio falls two or three-fold (depending on the country and histologic type of lung cancer) by 15 
years after the cessation of smoking (Khuder et al. 2001, Wakai et al. 2001).  
           These facts indicate the existence of other mechanisms (in addition to smoking) that 
contribute to the increase in lung cancer risks in modern populations. The elevated proportion of 
individuals susceptible to cancer in developed countries (discussed below) may play a substantial 10 
role in such a mechanism. This suggestion does not exclude smoking - an established carcinogen 
that has been confirmed in many studies. However, the fact that smoking elevates cancer risks 
does not mean that any observed increase in cancer risks is due solely to smoking. 
 
3.5 Why Has the Overall Cancer Risk Increased in the Former East Germany and the 
Soviet Union? 
Figure 4 shows age-specific cancer incidence rates in East and West Germany before 
reunification, by sex. 
 
  Fig. 4 about here 
 
We see from this figure that the cancer incidence rates were higher in West Germany (an 
economically more developed region) than in East Germany (an economically less developed 
region) before reunification, both for males and females. The former East Germany had a high 
density of industrial plants and a high level of environmental pollution. After reunification, many 
industrial enterprises were closed or equipped with new, environment friendly technology. As a 
result, the level of industrial pollution declined substantially. Paradoxically, the overall cancer 
risk in the former East Germany increased during that time. A similar trend was observed in 
Russia. After the collapse of the Soviet Union, many industrial plants were closed, too, leading 
to a lowering of environmental pollution (Health in Russia 2000).  In consequence, the 
ecological situation in the country improved, but the overall cancer risk increased nevertheless 
(Figurer 5(1)).  
 
Fig. 5(1) about here  
 
The figure shows that a steady increase in cancer incidence rates took place 1980-1999 in 
Russia, with the collapse of the Soviet Union in 1991 having had no noticeable effects.  
           The trends in cancer incidence rates in Russia and East Germany therefore seem not to be 
a concomitant of declining industrial pollution. A similar conclusion applies to smoking. The 
proportion of smoking males has remained almost constant (about 70 percent) in Moscow for 
many decades (McKee et al. 1998), while exposure to carcinogens related to tobacco smoking 
has decreased. This is because modern tobacco products have a significantly lower content of 
nicotine and tar than 50 years ago. Surprisingly, under these more favorable conditions, the male 11 
lung cancer incidence rate in Moscow increased rapidly until the 1990s, and began its 
deceleration only in the last decade of the century. The rate is still much higher today than in the 
past. Other smoking-related cancers (e.g., of the esophagus) have not shown favorable trends in 
Russia at all (Figure 5(2)). 
 
Fig. 5(2) about here  
 
               Thus, an increase in the cancer incidence rate in East Germany and Russia has been 
observed despite decreased exposure to some established environmental carcinogens. This 
paradoxical behavior of cancer rates is possibly due to the following reasons:  
(1)  The latent periods for lung and some other cancers are much longer than assumed.  
(2) Exposure to new carcinogens, or to those that were less prevalent in the past, has increased. 
(3) Individual susceptibility to carcinogens, including those existing in the environment for a 
long time, has increased.  
The first explanation does not have strong empirical support. The second seems realistic. 
It implies that economic progress is accompanied by a change in exposure structure to 
carcinogens rather than a simple increase in carcinogenic load (e.g., exposure to soot at home has 
been replaced by the exposure to pollution from car exhausts). The change in the spectrum of 
prevalent carcinogens elevates cancer risks even without an increase in total carcinogenic 
burden. This is because long-term (multigenerational) exposure of a population to a particular 
carcinogen favors the survival of more resistant individuals (e.g., smoking men with a lowered 
expression of the CYP1A1, a nicotine-metabolizing enzyme). When a new carcinogen appears, it 
takes time for the population to adapt to it. During this time, cancer risk is elevated, and after the 
adaptation declines. The third reason will be discussed in detail in the next section. 
 
4 Increased Proportion of Individuals Susceptible to Cancer   
4.1 How Does Economic Progress Increase Susceptibility to Cancer? 
Improved diagnostics and increased carcinogenic burden do not explain in full the association 
between the overall cancer risk and economic progress. Is this increase partly due to a higher 
proportion of individuals who are more susceptible to cancer in more developed countries?  
           First, let us address how increased susceptibility to a disease arises, using a simple 
example of allergy. Similar to cancer, the risk of allergic diseases (e.g., asthma and atopic 
dermatitis) drastically increased during the second half of the last century. It is also higher in 12 
more developed countries compared with less developed ones, even after adjustment for 
differences in diagnostic criteria (Trepka et al. 1996, Ukraintseva 1998). However, the majority 
of factors that directly induce allergic reaction (e.g., eggs, milk, pollen, wood or home dust) are 
natural and have been present in the human environment since thousands of years. These factors 
are not an exclusive feature of the more developed countries. Almost all people (in both more 
and less developed countries) are exposed to these natural substances, mostly without harm. 
Some individuals, however, react pathologically. This means that natural substances themselves 
do not cause the disease. Increased vulnerability of an organism to a normal environment is the 
true cause, possibly because its immunity is affected from factors associated with economic 
progress and a Western life-style. 
         Concerning vulnerability to cancer and respective morbid risks, we emphasize several 
groups of such factors: 
(1) Improvements in medical care, hygiene, and living conditions that “relax” environmental  
     selection and favor an increase in the proportion of individuals prone to chronic   
     inflammation (the latter promotes cancer; Pozharisski et al. 1979,  
     Coussens and Werb 2002). 
(2) Some nutritional products and medicines (of those prevalent in developed  
      countries) that increase the vulnerability to cancer by affecting the metabolism of   
      established carcinogens or favoring the chronic inflammation.  
(3) Some factors attributed to the Western life-style (such as a higher parental age or food  
      enriched with growth factors) that influence the parameters of individual aging and  
      vulnerability to cancer in a way that increases both longevity and cancer risks in the      
      populations of developed countries.  
 
4.2 How Improvements in Health standards Increase the Proportion of Individuals 
Susceptible to Cancer  
The higher the economic development of a country, the better the living standard and the quality 
of medical help in that country. These improvements lead to a “relaxation” of environmental 
selection and increase the proportion of individuals with various genetic and immune disorders 
in a population (Vogel and Motulsky, 1997; Ukraintseva, 1998). Improved medical and living 
conditions favor the survival of frail individuals, who are biologically more vulnerable to disease 
and would have died in the past. Besides, the immune system is not sufficiently trained under the 
improved conditions, and this also promotes rising vulnerability during an individual’s life. The 
increase in the proportion of vulnerable individuals at young, adult, and old ages contributes to 13 
the higher risks of common diseases, including cancer, in developed countries. Below, we 
explore this possibility. 
Improved survival during childhood. The decline in infant and childhood mortality was 
especially pronounced between the beginning of the last century and the 1980s. Today, survival 
during childhood is very close to the natural limit of 100 percent in developed countries. For 
instance, the infant mortality rate in the United States was about 3 percent of live births in 1950, 
around 1.3 percent in 1980, and about 0.7 percent in 1997 (Health US 2001). Most newborns in 
developed countries now reach the reproductive age. This radical improvement in survival is 
largely due to a decline in mortality from infectious disease, particularly from severe respiratory 
and intestinal infections. Contrarily, until recently, childhood mortality (up to 5 years) was nearly 
20 percent in some regions of the least developed countries, such as India. This indicates that the 
pressure of environmental selection is much higher in the least developed countries than in the 
most developed ones.  However, improved survival in more developed countries has its shadow 
side. Because almost all children (including those with immunity defects) survive, the proportion 
of children that are internally more susceptible to diseases is higher in more developed countries. 
This explains in part the paradox divergence between lower mortality from all causes and higher 
morbidity of various immune disorders (e.g., asthma, allergy, and chronic tonsillitis) in the 
children of the developed countries as compared to the less developed ones (Ukraintseva 1998). 
   Survival at adult and old ages. Adult and old-age survival rates also have been 
substantially increasing, particularly since 1950 (Vaupel et al. 1998) owing to new successful 
treatments of adult diseases with high fatality rates in the past (e.g., myocardial infarct, stroke, 
hepatitis, pancreatitis, tuberculosis, diabetes, and gastric ulcer). The efficient management of 
infectious diseases common in the young as well as the old (e.g., the flu and diarrhea) has been 
contributing to rising adult survival rates, too. Many people who would have died from these 
diseases in the past survive the same conditions today. However, they probably remain more 
vulnerable to pathologies, including cancer, compared to those who would have survived in the 
past without treatment, as the following examples show.  
How improved survival from infections could elevate cancer risk. Suppose there is a 
frail person, who is more vulnerable to infection than his or her peers because of an inherent 
insufficiency in the immune response, for instance. The person survives nevertheless a number 
of infections with the help of new antibiotics. However, he or she continues to be more 
susceptible to the infection because the original deficit in immunity still persists. This results in a 
higher probability of developing chronic inflammation. The chronic inflammation, in turn, is one 14 
of the major cancer risk factors (Pozharisski et al. 1979, Coussens and Werb 2002). An increase 
in the survival of people who are vulnerable to infections therefore increases the prevalence of 
chronic inflammatory conditions and thus may elevate cancer risks in a population.  
         Associated trends in disease morbidity linked to chronic inflammation provide support for 
this view. Chronic inflammation is a base not only for cancer but also for allergic disorders (e.g., 
asthma). Similar to cancer, the risk of asthma increased substantially in many countries during 
the past decades (Akinbami and Schoendorf 2002, Soriano et al. 2003). This increase, too, is 
linked to economic progress. Several studies indicate that vulnerability to asthma is correlated to 
cancer vulnerability. A meta-analysis performed by Santillan et al. (2003) revealed significant 
increases in cancer risks (about twice in average) unrelated to smoking among asthma patients. 
Our preliminary study of old individuals from National Long Term Care Survey (NLTCS), aged 
65 and above in 1999, confirms this finding (Ukraintseva, Michalsky, and Yashin - unpublished 
data). We found an almost two-fold increase in cancer prevalence among females who reported 
asthma in the anamnesis. These results indicate that an increased proportion of individuals prone 
to chronic inflammation is an important factor in the rise cancer risks in developed countries. 
How improved survival from stroke or myocardial infarct could elevate cancer risk. 
Another example of dependent pathologies concerns an intriguing trade-off between 
vulnerability to cancer and stroke (as well as cancer and ischemic heart disease or myocardial 
infarct (MI)), which is based on inter-individual differences in the intensity of apoptosis in post-
mitotic cells (e.g., mature neurons and cardiomyocites). When an individual has a high 
susceptibility to apoptosis in his or her cells (e.g., due to low cellular resistance to environmental 
stress or an inherently higher activity of the apoptotic signal), then this individual has a higher 
risk of death in case of a stroke or MI, but a lower risk in the case of cancer. Why is this the 
case?  
         With strokes, the higher activity of the apoptotic signal means that a relatively high number 
of nerve cells will die from damage caused by ischemia, consequently leading to a higher 
number of destroyed areas and affected nerve connections in the brain as well as a higher 
probability of paralysis, dementia, and death from the stroke. A similar mechanism relates to 
ischemic heart disease or MI. With cancer, by contrast, the higher intensity of apoptosis will 
result in greater chances of surviving the disease due to the elevated susceptibility of cells to 
treatment (e.g., chemotherapy or radiation).  15 
       In the opposite situation (i.e., a lower activity of the apoptotic signal), a greater number of 
neurons survive ischemia, so that the survival of stroke patients increases. However, the lower 
apoptotic activity would simultaneously mean better chances of cancer cell survival.  
       A number of studies confirmed that neurons die from apoptosis in oxygen-deprived brains 
and that the lower activity of the apoptotic signal leads to the better survival of neurons after 
stroke-induced ischemia (reviewed in Barinaga 1998). This finding suggests new approaches for 
the treatment of the consequences of stroke (as well as myocardial infarct). Preliminary results of 
several current trials (e.g., the treatment of acute stroke with DP-b99, an anti-apoptotic 
compound of D-Pharm company) are demonstrating that medicated suppression of apoptosis 
applied after the stroke improves the survival of the patients. The lowered level of apoptosis has 
shown to be associated with a higher resistance of tumor cells to anti-cancer therapy, leading to 
elevated mortality from cancer (Haffty and Glazer 2003). A large study of a cohort of 10,923 
male coronary patients in Israel revealed a significantly increased total risk of cancer in men with 
coronary heart disease compared to the general population (Reicher-Reiss et al. 2001). This 
excess was mainly due to cancers of the lung, bladder, and colon – sites that are among the most 
prevalent today. 
         Thus, we assume that individuals who survived a stroke, heart disease, or MI could in part 
be more vulnerable to cancer (e.g., due to an innately lowered activity of the apoptosis) 
compared to their peers who died from these pathologies and were eliminated from the 
population. Increasing the number of such survivors favors an increase in the proportion of 
cancer-prone subjects in the population. 
Cancer incidence in countries with short and long histories of economic growth. Our 
hypothesis about an increase in the proportion of individuals who are more vulnerable to cancer 
implies that countries with a short history of high economic development (20-30 years) manifest 
a lower overall cancer risk than countries with a long history of economic development, 
particularly at old ages. This is because old individuals in rapidly developing countries have been 
experiencing a high quality of life only since recently, whereas they faced more difficult living 
conditions earlier in their life. In such conditions, robust individuals are more likely to pass 
environmental selection and reach old age. This is possibly a reason for the lower proportion of 
individuals who are vulnerable to cancer among the elderly in recently developed countries 
compared to countries with long histories of economic growth. That is, overall cancer incidence 
rates should be lower with the former scenario. Figure 6 confirms this prediction.  
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Figure 6 about here 
 
The figure shows that age-specific cancer incidence rates in Japan, Singapore, and 
Kuwait (the "young" developed countries) are lower than in the United States, the United 
Kingdom, and Switzerland (the "old" developed countries) despite similar standards of cancer 
diagnostics across these countries. 
Differences in cancer incidence among migrants.  IARC data on migrants to Israel 
(IARC 1997) allows for a comparison of cancer risks in adult Jews who presently live in Israel 
but were born and grew up in other countries. Figure 7 shows different cancer incidence rates at 
the same age for groups of different origins. 
 
Fig. 7 about here 
 
One can see that Jews born in Africa (a less developed region) have lower risks of cancer than 
those born in Europe (a more developed region).  The discrepancy is unlikely to be due to 
differences in cancer diagnostics because all people under study are citizens of the same country. 
This data support our view that environmental selection in less developed countries favors the 
survival of robust individuals who are less vulnerable to cancer. 
Not sufficiently trained immune system. Another reason for the observed differences in 
cancer rates among migrants in Israel (Figurer 7 above) is that the immune system of the 
individuals that grew up in less developed regions is stronger than that of individuals from the 
more developed regions. This is because it is better “trained” by more frequent stimulation with 
antigens. Training the immunity may create a hormesis effect (i.e., where a toxic substance acts 
like a stimulant in small doses, and it may help to strengthen the organism in its fight against 
more harmful substances in the future). Indeed, children of the more developed countries are less 
exposed to negative environmental factors (e.g., drinking and bath water containing wide 
spectrum of bacteria). As a result, their immune system is not sufficiently stimulated to fight 
dangerous antigens that appear later in life. This enhances their chances of developing chronic 
inflammatory conditions.  
       Some researchers directly connect excessive disinfection and a lack in the stimulation 
(especially in early childhood) of the host immune system with infectious (e.g., microbial, viral, 
and parasitic) factors in westernized communities with the increased risk of chronic 
inflammatory diseases, including skin allergies and asthma (Kramer et al. 1999, Strannegard and 17 
Strannegard 1999, Fujita 2000, Lovik 2000, Imai and Fujita 2004). Chronic inflammation, in 
turn, may increase cancer risks in the way discussed above.   
        Thus, an increase in population vulnerability to cancer can be attributed not only to better 
living conditions that improve the survival of frail individuals, but also because these living 
conditions may increase vulnerability during the life of an individual.            
 
Summary of Section 4.2  
(1) The increased proportion of individuals suffering chronic inflammation is likely to contribute 
to higher cancer risks in more developed countries. Improvement in health standards “relax” 
environmental selection and favor the survival of frail people who have weakened immunity and 
are prone to develop the chronic inflammation. The latter is one of key cancer risk factors.  
(2) Survivors of several common diseases with high fatality rates in the past (e.g., stroke and MI) 
may have a greater predisposition to cancer. One possible mechanism involves the trade-off in 
apoptotic response to cell damage between the individuals predisposed to cancer and stroke or 
MI. The increased proportion of stroke, heart disease, and MI survivors may have contributed to 
the higher cancer rates in more developed countries.  
(3) Excessive disinfection and hygiene may reduce the adaptive capabilities of an organism. 
Overprotection against environmental exposures results in a lack of training the immune system 
sufficiently to combat illness.  This, in turn, elevates the chances of developing chronic 
inflammation, favoring an increase in cancer risks. 
 
4.3 How the Western Life-Style Increases Vulnerability to Cancer 
Many behavioral and dietary habits are common in economically prosperous countries but not 
typical of populations in less developed ones. These habits reflect the Western life-style. In this 
section, we discuss the Western pattern of food consumption and the number of contemporary 
medicines. They are not directly carcinogenic themselves, but they may increase vulnerability to 
cancer by, e.g., affecting the metabolic ways of processing internal carcinogens and/or favoring 
chronic inflammation in an organism.  
 
4.3.1 The Western Pattern of Food Consumption.  
The western pattern of food consumption is characterized by a high content of animal protein 
(from meat, eggs, and cheese), fat, and purified sugar, as well as a low content of crude plants 
and grains in the everyday diet. This pattern is typical of developed countries, but not of the 18 
developing ones. A number of studies suggest a causal connection between the spread of 
Western dietary habits and changes in the prevalence of cancer sites in a country.  
Protein and fiber. It has been shown that individuals with relatively high meat 
consumption face up to twice the risk of colon cancer (Willett 1989, Kearney et al. 1995, 
Tiemersma et al. 2004) and a less consistent but nevertheless increased risk of male prostate 
cancer (LeMarchand et al. 1994, Giovannucci et al. 1993).  
        Kagawa et al. (1978) found that the traditional food consumption pattern in Japan in the past 
was characterized by a high proportion of crude grain (barley), and a low proportion of any kind 
of animal protein. Since the 1950s, this diet has been gradually replaced by one that includes a 
high proportion of protein and a low proportion of barley. Other components of the Japanese diet 
(e.g., vegetables) did not experience large changes during the same period. The colon cancer 
incidence rate has been increasing drastically in Japan since then, while the rate of stomach 
cancer has been decreasing slightly (Figure 8).  
 
Figure 8 about here 
 
       Changes to Japanese food patterns may be partly responsible for these trends in colon and 
stomach cancers. Excessive crude fibers in food harms the stomach’s mucous membrane and 
promotes inflammation, thus increasing the vulnerability to stomach cancer. Decreased fiber 
intake diminishes this harm and reduces stomach susceptibility to cancer. At the same time, it 
suppresses intestinal motility and may elevate the risks of colon cancer. This is because motility 
prevents the intestine from festering. Festering creates an environment conducive to the 
development of bacteria imbalance in the intestine. This imbalance, in turn, favors carcinogenic 
production by colon bacteria, e.g., E.coli (Kearney et al., 1995; Monson and Walsh 1996; Falk, 
1998; Parsonnet, 1999). An increased intake of meat also promotes food festering in the intestine 
accompanied by bacteria imbalance and increasing internal carcinogenic exposure (Kearney et 
al., 1995; Parsonnet, 1999).  
 
4.3.2 New Medicines 
Some medicines and dietary supplements that are prevalent in developed but not in developing 
countries may increase the vulnerability of an organism to cancer, although they have not been 
established as carcinogens themselves. The following example describes a possible mechanism 
of such an influence.  19 
A well-studied chemical, benzpyrene, is a non-direct carcinogen. It needs to be 
metabolically processed in an organism before it becomes harmful. First, an oxidative enzyme 
(e.g., Cytochromes P450) decomposes benzpyrene into intermediate products of the metabolism. 
Several of these products (e.g., phenol) are already carcinogenic. Some other substances of the 
organism (e.g., glutathione) bind these carcinogenic products to deactivate them and take them 
out of the metabolism (see e.g., Napalkov et al. 1987). If there is an appropriate balance between 
Cytochromes P450 and glutathione in a cell, then the carcinogen is quickly deactivated without 
harming the organism. However, if the amount of glutathione is not in balance with the amount 
of Cytochromes P450, the carcinogen deactivation process is delayed or incomplete. As a result, 
carcinogenic metabolites accumulate in the organism and increase the risk of cancer.  
               This simple example shows that metabolic balance is an important factor in the 
resistance of an organism to a carcinogen. Uncontrolled intake of medicines and dietary 
supplements affects the synthesis and amount of many substances in the organism. This, in turn, 
may disturb the delicate balance of events and processes leading to the neutralization of 
established carcinogens and elevate an organism’s vulnerability to cancer. A number of studies 
on the simultaneous exposure to carcinogens and non-carcinogenic drugs support the existence 
of such a mechanism.  
Paracetamol. Paracetamol (Acetaminophen, Tylenol, Contac) is a non-prescription 
antipyretic, which has been used extensively in developed countries since 1946. The drug is not 
classifiable by IARC in its carcinogenicity to humans. However, animal experiments have shown 
that paracetamol enhances the incidence of renal adenomas induced by an established 
carcinogen, N-nitrosoethyl-N-hydroxyethylamine (IARC Monographs 1990). That is, 
paracetamol, being not harmful on its own, increases the susceptibility of an organism to the 
carcinogen. 
Antibiotics. Some prevalent antibiotics that are thought to be non carcinogenic in humans 
may enhance individual susceptibility to established carcinogens. Chloramphenicol, an antibiotic 
widely used since the 1950s, is an example. Its application increased the incidence of lymphomas 
induced by an established carcinogen in mice, while the drug in itself did not show a 
carcinogenic effect (IARC Monographs 1990). This mechanism, again, may affect the 
metabolism of the established carcinogen in an organism.  
Trade-off effects of antibiotics on risks of separate cancers. Antibiotics may have 
different and sometimes opposite effects on the risks of separate cancers. Earlier, we have 
discussed the role that new food consumption patterns play in prompting changes in the 20 
incidence rates of colon and stomach cancers in Japan. The introduction of new medicines is 
likely to make a contribution to the divergence between the trends in the incidence rates of these 
cancers as well. The parallel increase in colon cancer and the decrease in stomach cancer can be 
explained not only by changes in the food patterns, but also by the population-wide exposure to 
new prevalent antibiotics.  
(1)Antibiotics and stomach cancer. A number of studies discussed in the IARC 
monographs (1994) established an association between seropositivity for the H. pylori bacteria 
and stomach cancer. An estimate of the relative risk was about four times the natural risk of this 
cancer. A possible mechanism involves the cancer promoting effects of chronic inflammation 
accompanying the infection. The prevalence of H. pylori infection is substantially lower in 
developed countries than in developing ones. In both, the prevalence is higher in the lower 
socioeconomic classes. A progressive reduction in the rate of this infection in successive birth 
cohorts of the developed countries (IARC Monographs 1994) is held to be the result of improved 
hygiene and the spread of antibiotics (e.g., metronidazole) which can destroy H. pliory bacteria. 
Antibiotic treatment may therefore decrease the risks of stomach cancer.  
(2) Antibiotics and colon cancer. Many antibiotics are known to suppress normal 
intestinal flora, thereby promoting bacterial imbalance in the colon. As mentioned above, this 
imbalance often results in the suppression of the bifido-bacteria and promotion of the E.coli 
bacteria (Falk et al. 1998). The latter have a propensity to transform normal metabolic products 
(e.g., bile acids) into internal carcinogens, thereby increasing the risk of colon cancer (Parsonnet, 
1999). Antibiotics may also influence the metabolism of external carcinogens. Metronidazole, an 
antibiotic which can destroy H. pilory and decrease the risk of stomach cancer, increased the 
incidence of colon cancer induced in rats by the administration of an established carcinogen 
(Sloan et al. 1983, IARC Monographs 1987).  
Thus, antibiotics can influence the carcinogenic metabolism and inflammatory processes 
in an organism, increase the organism’s vulnerability to some cancers and decrease its 
vulnerability to others.  
Menopausal/postmenopausal estrogens. Menopausal and early postmenopausal estrogen 
therapy is common in developed countries, while still rare in developing countries. This could in 
part be responsible for the variation in incidence rates of female hormone-dependent cancers 
among these two groups of countries (IARC Monographs 1999). Postmenopausal estrogen 
therapy has been shown to substantially increase the risk of female endometrial cancer. At the 
same time, the therapy is associated with reduced risks of colon and cervical cancers (IARC 21 
Monographs 1999).  It is also protective against osteoporosis. The risk of breast cancer was not 
reliably shown to rise under postmenopausal estrogen therapy. Among the original articles, risk 
estimates ranged from that which is considered protective to that which has an adverse effect in 
women who ever used estrogens, and no consistent quantitative effects of estrogens on breast 
cancer risk were found (Henrich 1992). In some studies, the risk increased only slightly or 
insignificantly after a period of five years or more (IARC Monographs 1999). In general, the 
findings do not support increased risks of breast cancer in women who took postmenopausal 
estrogens; however, premenopausal women who used estrogens have an increased risk of breast 
cancer of about 30 percent after fifteen years of exposure (Steinberg et al. 1991).  
         Thus, the recent increase in the risk of breast cancer, observed primarily at ages over 65, 
can be related to the long-term effects of premenopausal exposure to estrogens (e.g., as 
contraceptives) rather than to the short-term effects of postmenopausal therapy. 
             We do not consider here the widely-discussed results of two large Women’s Health 
Initiative (WHI) Postmenopausal Hormone Therapy Trials (the first with estrogen plus progestin, 
and the second with estrogen alone). These trials have recently been concluded because of 
harmful effects of the therapy on risks of stroke and some other health disorders. However, a 
majority of women in these studies were aged 65 and above at the start of exposure to the 
hormone replacement therapy (HRT). HRT at this late age is still not common in developed 
countries. This therapy is often applied as symptomatic treatment of menopausal symptoms at 
ages 48-55 (around climacteric), and rarely later, because relevant symptoms tend to cease 
spontaneously by age 60 (Gosden 1985). Therefore, it makes little sense to discuss the results of 
the WHI studies, when explaining worldwide increases in cancer risks during several past 
decades. 
Oral contraceptives combined. Another female hormonal treatment, oral contraception 
for pregnancy prevention, is more prevalent than postmenopausal therapy. Oral contraceptives 
usually include both estrogen and progesterone. This treatment has been popular in developed 
countries since the 1960s. Today, about 90 million women worldwide use ‘the Pill’ for 
contraceptive purposes. It has protective effects against endometrial and ovary cancers in 
women, but has been shown to increase the risk of liver cancer. The protective effect against 
endometrial cancer is mostly related to progesterone, not estrogen action (IARC Monographs 
1999). Starting in the 1970s, the decline in female endometrial and ovarian cancer incidence 
rates, as well as the increase in the incidence rate of liver cancer in the United States, may 22 
therefore in part be due to the widespread exposure of American women to combined hormonal 
contraceptives.  
         The effect on the female organism of estrogen alone as well as in combination with 
contraceptives is very complex and depends on age (stage of ontogenesis) and tissue.  Cancer 
promoting properties can be related to the estradiol-associated stimulation of growth hormones 
release (Veldhuis et al. 2004) and excessive cell proliferation, while cancer protective properties 
may be associated with increased regenerative potential and competitive abilities of normal host 
cells surrounding a transformed cell or latent tumor (Ukraintseva and Yashin 2003, 2004). 
 
4.3.3 Chemicals Used at Home 
Chemicals used at home are tested for carcinogenic properties before market introduction: They 
therefore are unlikely to be carcinogenic or mutagenic themselves. However, pre-market testing 
of chemicals usually does not take into account that these products may occasionally be 
consumed with drink or food, because they are intended for use outside the organism only.  The 
problem is that the clearance of surfaces (e.g., glasses and plates) from such chemicals is often 
poor (particularly in small private food services), and their residual on the surfaces (e.g., on 
wineglasses) may go to the organism, accumulate and finally be sufficient to harm the organism. 
Unfortunately, there are very limited studies on this important topic (e.g., Travier et al. 2002) and 
no definite conclusion can be drawn to date. 
 
4. 4 Factors of Economic Progress that Increase both Longevity and Vulnerability to 
Cancer 
4. 4. 1 Cancer and Aging: A Trade-Off?  
A paradox feature of economic progress is the parallel increase in life expectancy and cancer 
morbidity. Can these increases be causally linked? Some factors associated with high economic 
development and a Western life-style (e.g., food enriched with growth factors and postponed 
childbirth) influence the parameters of organism’s aging and development (e.g., the length of 
growing and reproductive periods, the rate of growth, the height and weight), so that it could 
result in a postponement of aging manifestation in individuals. These same factors may enhance 
organism’s susceptibility to cancer (e.g., because of protracted exposure to inner cancer risk 
factors, such as growth hormones). That is, there are factors that may favor an increase in both 
longevity and cancer risks in populations of developed countries. Below, we discuss the evidence 
available on the possibility of such a scenario.   23 
 
4. 4. 2 Exposure to Growth Factors 
Growth factors in cancer. Excess of internal growth factors is considered to play an important 
role in cancer development and is associated with increased risk of developing several common 
cancers (Giovannucci 1995, Pelengaris 2002, Pollak et al. 2004). The mechanism involves a 
higher cell proliferation rate favoring malignant transformation, the anti-apoptotic effects of 
growth factors, and increasing rates of latent tumor growth in individuals with higher levels of 
internal growth factors (e.g., IGF1) (Pollak et al. 2004).  
Growth factors in aging. As for aging and longevity, there are limited data on increasing 
life span due to excessive growth factors or stimulating respective signaling pathways in cells. It 
has been demonstrated that the overexpression of a growth factor receptor (tyrosine kinase 
receptor, tkr-1) improved survival (by an average of 65 percent) and stress resistance in 
nematodes (Murakami and Johnson 1998). Ruiz-Torres and Soares de Melo Kirzner (2002) 
showed on a sample of 205 healthy individuals aged 19-93 that old males with IGF-1 levels, 
similar to young ones, did neither have an age-dependent decrease in serum testosterone and lean 
body mass nor an increase in fat body mass. That is, they were biologically younger than their 
peers.     
        There is also non-direct evidence as to humans. It has been shown that the long-term use of 
estrogens significantly improves overall female survival at old ages (regardless of separate 
morbid risks). The relative risk of death from all causes varied between 0.5-0.7 (Bush et al. 1983, 
Petitti et al. 1987, Criqui et al. 1988, Henderson 1991, Ettinger et al. 1996, Cauley et al. 1997, 
Jansen et al. 2002).  Other studies suggest that one of the primary effects that estrogens have is 
that they stimulate growth hormone (GH) release. The effect of estrogens on survival is possibly 
due in part to the GH effect.  
        The mechanism of influencing growth factors on cancer and aging involves apoptosis. Data 
indicates that internal growth factors play a role in cell survival and tissue regeneration by 
inhibiting apoptosis (Wood and van der Kraak 2002, Fischer-Posovszky et al. 2004). As for 
cancer, growth factors contribute to tumor growth through the inhibition of apoptosis (Harris et 
al. 2002). Thus, one can suggest a connection between prolonged exposures to growth factors 
and increased both cancer risks and longevity.  
 Height. New generations become taller, and the proportion of tall individuals increases 
over time in more developed countries. Tallness and large body size are both associated with 
increased risks of breast cancer in postmenopausal women (Micozzi 1993, Stoll 1995, Hunter 24 
and Willett 1993). Taller people also appear to face higher risks of colon cancer (Miccozzi 1993, 
Monson and Wals 1996). An increase in height is usually attributed to enriched nutrition. The 
carcinogenic effect of height is attributed to greater and longer exposure of tall individuals to 
internal growth factors.  
            So far, the exact relation between height and longevity is not clear. Human populations 
show indeed an increase in both height and longevity. Species of larger size commonly live 
longer. However, shortness is often associated with longer life within the same animal species, 
e.g., mice (Bartke 2000). Additional studies are, therefore, needed.  
  Length of growth period. Prolonged exposure to internal growth factors increases the 
length of the growth period and postpones age at growth cessation. This, in turn, may lead to the 
postponement of aging manifesting in individuals.  
 Age at growth cessation and aging postponement. The organism may compensate deleterious 
age-associated changes better when it continues to grow than when it ceases growth. If the yield 
of newly appearing undamaged cells overrides that of old damaged cells, the organism has a 
higher ability to restore tissues and postpone aging. Differences between species in longevity are 
associated with differences in the length of the growth period. Interestingly, calorie restricted 
(CR) mice (which live longer and age slower) have shown a clear association between longevity 
and the length of the growth period. They increase weight over a longer period of time than ad 
libitum fed mice, even though the former have lower weights at all ages (Sohal and Weindruch 
1996). Unfortunately, there are few studies on the influence of age at growth cessation on human 
longevity because of obvious study limitations, e.g., the increment in height needs to be 
measured before ages 25-30, whereas differences in old age survival appear much later in life. It 
is difficult to find human data that contain longitudinal information from youth until oldest old 
ages. Note that the age at growth cessation does not automatically correspond to the age of 
sexual maturation (e.g., start of menarche in females). In human societies, the age of menarche 
has been decreasing with economic progress, while the age at growth cessation has been 
increasing in parallel, so that both growth and reproductive periods have been increasing in 
length. 
 Age at growth cessation and cancer risk. There are indirect indications on the role that age at 
growth cessation plays in cancer risks.  A comparison of incidence rates for 26 cancer sites 
between first and second generation immigrants using native Swedes as a reference suggests that 
the first two decades of life are most important in setting the patterns of cancer development later 
in life (Hemminki 2002
1, 2). Cancers in first generation immigrants, who arrived in the country at 25 
ages 20 and over (i.e., at the end of the growth period) followed the rates in the countries of 
origin, while in the second generation they approached the rates witnessed in the host country. 
This means that the organism is more vulnerable to environmental carcinogens while it is 
growing and exposed to a higher amount of internal growth factors. The prolongation of the 
growth period (postponed age at growth cessation) may elevate cancer risks.  
           We thus hypothesize that there is a causal association between a longer growth period, 
cancer risk, and longevity. We are currently testing this complex relationship with available 
longitudinal human data sets. As mentioned, human data sets that are keeping individual 
information from youth until old age are rare. We therefore also use data from rodent life-term 
experiments to address this issue. 
 
4. 4. 3 Length of Reproductive Period 
Age of menarche. Enriched nutrition and obesity lead to earlier maturation, which is manifest in 
a decreasing age of menarche. In England and the United States, this index declined from a mean 
age of 15 at the beginning of the 20
th century to a mean age of 13 in the 1960s (Sandler et al. 
1984, Poppelton and Brown 1966). In less developed regions, e.g., Ethiopia, Egypt, Nepal, 
Kyrgyzia, and Papua New Guinea, the median age of menarche varied from ages 14 to 18 in the 
1970s (Pawson 1976, Tanner 1981).  In West European and North American countries (which 
are more developed regions), it varied from 12.5 to 13.5 in the same period. The age of menarche 
has a remarkable association with socioeconomic class. Women from low social classes in Tunis, 
Iraq, Singapore, and Turkey reported a median age between 13 and 14, while their native 
counterparts from high social classes reported a median age between 12.4 and 13.6. Even in the 
19
th century, the mean age of menarche was lower in the middle-class samples (about 14.5) 
compared to the working class samples (about 16) (Tanner 1981).  
             In a study of 3,993 breast cancer cases and 11,783 controls, the age at menarche was 
found to be a cancer risk factor among pre-menopausal and post-menopausal women. A delay of 
two years corresponded to a 10 percent reduction in breast cancer risk (CI 6-15 percent). That is, 
later menarche reduced the risk of developing this cancer (Hsieh et al. 1991). 
   The age of menopause. The median age of menopause has increased with economic 
progress and a Western life-style. This age varies from 44 to 49 in less developed regions (e.g., 
India, South Africa, and Papua New Guinea) to 50 to 52 in more developed regions (e.g., 
England, the United States, and the Netherlands) (McKinaly et al. 1972, MacMahon 1966, van 
Keep et al. 1979).  26 
            Late menopause is associated with a decreased risk of death at old age (Snowdon et al. 
1989). Women who were menopausal after age 53 had a significant reduction in mortality risk 
(with an odds ratio of 0.62) compared to women who experienced menopause before age 46 
(Jansen et al. 2002). The decline in mortality was due in particular to a reduction in mortality 
arising from cardiovascular disease. A study of 9,450 postmenopausal women in the Netherlands 
confirms this finding (de Kleijn et al. 2002). It revealed that women aged 52 years or above at 
menopause had a significant reduction (18 percent) in cardiovascular mortality (RR = 0.82) 
compared to those aged 44 years or less at menopause. Our preliminary study of aging, Danish 
Twins (LSADT), followed up 1995-2000, showed that a menopause age of 52 or over is 
associated with decreased chances of death from all causes in women older than 75 years 
(RR=0.83) compared to women who had menopause at the usual ages (49-51).  
            As for cancer, later menopause is associated with elevated risks of ovarian and 
endometrial cancers in postmenopausal women (de Graaff and Stolte 1978, Franceschi et al. 
1991). The data used by the authors indicate that there is probably a trade-off between the 
positive and negative effects of internal estrogens on cause-specific mortality, so that the 
resulting effect on the overall survival is positive.  
  A mechanism that involves prolonged exposure to estrogens. An explanation of how a 
longer reproductive period increases cancer risk as well as old age survival focuses on longer 
exposure of the female organism to internal estrogens. A decrease in the age of menarche and a 
rise in the age at menopause result in the prolongation of the reproductive period and hence the 
duration of exposure to internal estrogens in females. In turn, prolonged exposure to estrogens 
may result in different (and even opposite) effects on cancer morbidity and old age survival.  
         On the one hand, long-term therapy with estrogens increases the risk of several cancers 
(Steinberg et al. 1991, IARC Monographs 1999). On the other, plenty of studies demonstrate that 
regular exposure to estrogens significantly improves female survival at old ages (Bush at al. 
1983, Petitti et al. 1987, Henderson 1991, Ettinger et al. 1996, Cauley et al. 1997, Jansen et al. 
2002). Studies of hormonal treatment in women with menopausal symptoms (to cushion the 
deleterious effects of the climacteric) revealed that the treatment produces physiological anti-
aging effects and decreases the risk of age-related dementia (Yaffe et al.1998, LeBlanc et al. 
2001, Resnick and Henderson 2002,  Henderson 2004). Conjugated estrogens promote neuronal 
survival as well as reverse skin aging in pre-climacteric women. Ashcroft and colleagues (1999) 
found that delays in wound healing (which is an important aging biomarker) in the elderly is 
significantly diminished by topical estrogen in male and female patients.  27 
               Thus, there is probably a trade-off between cancer and longevity, influenced by age at 
menopause and exposure duration to endogenous estrogens. The trade-off may be in part due to 
the favorable action of pre-menopausal estrogens on the consequent risks of cardiovascular 
diseases (CVD). Indeed, the total survival largely depends on mortality from CVD and cancer. 
The fact that later menopause is associated with improved total survival implies that its 
protective potential against CVD is substantial. 
Giving birth at late age. Morabia and Costanza (1998) showed that age at first childbirth 
has increased in developed countries. Later age at first childbirth and null parity show some 
positive association with survival at old ages. Our preliminary study of aging Danish Twins 
(LSADT 1995-2000) revealed that an age of 40-43 at last childbirth is associated (although not 
significantly) with decreased chances of death in women older than 75 (RR=0.83) compared to 
women who had their last child before age 40. In animal studies, selection for late reproductive 
ability also resulted in an increased life span of flies (Rose and Charlesworth 1981).  
            At the same time, late age at childbirth is associated with elevated risks of several human 
cancers, in particular of the breast in mothers, childhood leukemia, and brain cancer in the 
newborn (Dupont and Page 1987, Wohlfahrt and Melbye 2001, Hemminki et al. 1999). The 
breast cancer risk rose significantly with age at first birth: Women who gave first birth after the 
age of 35  had a risk increase by 40 percent compared to mothers who experienced their first 
birth before the age of 20 (Ewertz et al. 1990, Dupont and Page 1987). A higher age of the father 
was associated with a rising susceptibility to an established carcinogen (N-nitrosomethylurea) in 
mice offspring (Anisimov and Gvardina 1995) and with an elevated risk of prostate cancer in 
human offspring (Zhang et al. 1999).  
          As an explanation of how late age at childbirth increases both cancer risks and longevity, a 
higher age at childbirth on the one hand is associated with an increase of genetic defects in 
progeny (e.g., chromosome aberrations). This may enhance the organism’s susceptibility to 
malignant transformation (Vogel and Motulski 1997). On the other hand, giving birth late may 
postpone aging of the female reproductive function.  
 Summary. Data from human and animal studies suggest that several factors of economic 
progress affect the parameters of individual aging and development in ways that increase both 
longevity and vulnerability to cancer. Prolonged durations of growth and reproductive periods in 
an individual lead to the postponement of the subsequent stages of aging, which in turn increases 
the potential longevity of species. At the same time, these changes increase exposure duration to 
internal growth factors and sex hormones (e.g., estrogens) which contributes to increased 28 
vulnerability to certain hormone-related cancers. This complex relationship between aging, 
health, and longevity is a very challenging phenomenon. It is a warning against simplified 
approaches to extend longevity without taking into account possible trade-offs between aging 
and health at old ages. Several trade-offs between morbidity and mortality and their possible 
mechanisms were discussed by Ukraintseva (2000), and Ukraintseva and Yashin (2003). 
 
5 Concluding Remarks 
 New insights and ideas concerning the mechanisms of cancer development in humans are 
generated from a comparative analysis of age patterns, time trends, and place differences in 
cancer incidence rates. The results of such an analysis, performed in this chapter, suggest that:  
(1) Improved cancer diagnostics does not explain in full the observed (until recently) 
increase in the overall cancer risk.  
            (2) There is no convincing evidence that elevated exposure to carcinogens is the only 
factor responsible for elevated cancer rates in developed countries.  
             (3) Several factors associated with high economic development and a Western life-style 
favor an increase in the proportion of susceptible to cancer individuals. These factors include 
(but not limited to): 
•   increasing the share of individuals prone to chronic inflammation (linked to relaxation of 
environmental selection); 
•   nutrition enriched with growth factors; 
•    a higher parental age.  
         (4) There are factors that enhance susceptibility to cancer and, at the same time, postpone 
aging manifestation in individuals. That is, they could favor increases in both longevity and 
cancer incidence rate in a population. 
         (5) Factors of economic progress that are responsible for decreased risks of some cancers 
(e.g., of the stomach and cervix) first of all include the successful prophylactics and treatment of 
relevant chronic inflammatory conditions (e.g., gastritis and cervicitis).  
          (6) Integrating the results of genetic, epidemiological, and clinical studies is critical to 
understanding observed trends in cancer incidence rate. More work systematizing knowledge 
from different areas of cancer research is needed to develop adequate measures that will help to 
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Fig. 1. Cancer incidence rate (average annual) in the USA (Connecticut), 1960-62 and 1988-92, and in
Japan  (Miyagi), 1962-64 and 1988-92 (IARC 1965-1997).
Cancer incidence rate (all sites) in the USA and Japan,




































Fig. 2. Lack of a positive correlation between the age-standardized cancer incidence rate (ASR) 
and five-year survival from cancer in the countries of the EU (EUCAN 1999).
Cancer incidence rate and survival of cancer patients
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Fig. 3(1). Increase in the lung cancer 
incidence rate, 1960-62 and 1988-
92, in Connecticut, by sex (IARC 
1965-1997). 
Fig. 3(2). Lung cancer incidence rate 
ratio of  (1988-92) to (1960-62), in 
Connecticut, by sex (IARC 1965-
1997). The rate has increased over 
time more rapidly in females than in 
males at all ages except the very old.
Lung cancer incidence rate in 1960-62 and 1988-92 
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Fig. 4. Cancer incidence rate in East and West Germany, 1988-92, average annual (IARC 1997).

































































Fig. 5 (1). Steady increase in the age-standardised cancer incidence rate (for all sites combined) in Russia,
1980-1999 (Health in Russia 2000).
 
 41 
Fig. 5 (2). Age-standardized cancer incidence rates for selected cancers in Russia, 1980-1999 (Health in 
Russia 2000). One can see a slight decline for lung cancer rates beginning in the 1990s, a steady  increase in 
the rate for colon cancer, an unchanged rate for oesophagus cancer, an increased rate for female breast 
cancer and a decreased rates for “infection-related” cancers (stomach and cervix).
Changes in the incidence rates (ASR) of selected cancers 



































Fig. 6. Male cancer incidence rates in developed countries with different histories of economic development (IARC
1997). Countries with newly developed economies for the last 30 years (Japan, Singapore, and Kuwait) exhibited lowe
cancer rates than countries with a long history of economic growth, such as the USA, Switzerland, and West Germany



































Fig. 7. Overall cancer incidence rate among Jews, who presently live in Israel, but were born outside the country  
(IARC 1997). Jews born in Africa/Asia exhibit a lower cancer incidence rate than Jews born in America/Europe  
or in Israel despite a similar quality of medical diagnostics available to all of them in Israel. 
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Stomach cancer incidence rate, Japan (Miyagi), 































Fig. 8. Change in colon and stomach cancer 
incidence rates in Japan (Miyagi), 1962-64 and 
1988-92 (IARC 1965-1997). 
The male colon cancer risk drastically increased 
1962-64 and 1988-92, while the stomach cancer 
risk slightly decreased (except old age) for the 
same period. 
 
 